Clinical Trials Logo

Filter by:
NCT ID: NCT04058353 Completed - Cystic Fibrosis Clinical Trials

A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

Start date: August 28, 2019
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy, safety and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for F508del and a gating or residual function mutation (F/G and F/RF genotypes).

NCT ID: NCT04056689 Completed - Parkinson's Disease Clinical Trials

Study to Evaluate DNL151 in Subjects With Parkinson's Disease

Start date: July 23, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL151 in subjects with Parkinson's disease.

NCT ID: NCT04055480 Completed - Type 1 Diabetes Clinical Trials

Closing the Loop in Adults With Type 1 Diabetes Under Free Living Conditions

AP@Home04_P3
Start date: August 10, 2019
Phase: N/A
Study type: Interventional

The main objective of this study is to determine whether home use of day and night closed loop insulin delivery under free living conditions applying faster insulin aspart (FiAsp) is non-inferior to home use of closed-loop applying standard insulin aspart. This is a double-blind, multi-centre, randomised, crossover design study, involving a run-in period followed by two study periods during which glucose levels will be controlled either by an automated closed-loop system using standard rapid acting insulin analogue or by an automated closed-loop system using faster insulin aspart in random order. Subjects will receive appropriate training in the safe use of closed-loop insulin delivery system. Subjects will have regular contact with the study team during the home study phase including 24/7 telephone support. The primary outcome is time spent in target range between 3.9 and 10.0 mmol/L as recorded by CGM during home stay. Secondary outcomes are the HbA1c, time spent with glucose levels above and below target, as recorded by CGM, and other CGM based metrics.

NCT ID: NCT04054921 Completed - ß-thalassemia Clinical Trials

Safety Study for Beta Thalassemia Subjects on PTG-300

TRANSCEND
Start date: May 10, 2019
Phase: Phase 2
Study type: Interventional

In this study will investigate long term safety and use of the PTG-300 in Beta Thalassemia patients.

NCT ID: NCT04054193 Completed - Clinical trials for Chemotherapy-induced Nausea and Vomiting

Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)

Start date: September 9, 2019
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of a 3-day intravenous (IV) fosaprepitant dimeglumine (MK-0517) regimen for the prevention of CINV in pediatric participants scheduled to receive emetogenic chemotherapy. Each participant was enrolled in Cycle 1 (on which the primary study objectives were based), consisting of the 3-day treatment cycle and 14 days of follow-up for a total of 17 days.

NCT ID: NCT04053998 Completed - Clinical trials for Pancreatic Neoplasms

Benchmarking Outcomes in Pancreatic Surgery - WhippleBenchmarks.Org

Start date: August 9, 2019
Phase:
Study type: Observational

The WhippleBenchmark 2 Collaborative study aims at defining benchmark criteria for best achievable outcomes after pancreaticoduodenectomy with portal vein resection.

NCT ID: NCT04053920 Completed - Aging Clinical Trials

Resistance Exercise Training at Different Intensities

Start date: March 1, 2018
Phase: N/A
Study type: Interventional

The aim of the current study, therefore, is to determine the feasibility of recruitment and adherence to resistance exercise training interventions performed at low and high loads, to volitional muscular failure, in a trial population that includes both healthy and frail older people.

NCT ID: NCT04053881 Completed - Plaque Psoriasis Clinical Trials

A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice

CIMREAL
Start date: August 21, 2019
Phase:
Study type: Observational

The purpose of the study is to assess the effectiveness of certolizumab pegol in patients with moderate to severe plaque psoriasis as part of routine clinical practice.

NCT ID: NCT04053764 Completed - Clinical trials for Sickle Cell Disease (SCD)

Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease

STEADFAST
Start date: December 10, 2019
Phase: Phase 2
Study type: Interventional

The goal of the study was to evaluate descriptively the effect of crizanlizumab + standard of care and standard of care alone on renal function in sickle cell disease patients ≥ 16 years with chronic kidney disease due to sickle cell nephropathy.

NCT ID: NCT04053686 Completed - Metabolic Syndrome Clinical Trials

An Intervention to Reduce Prolonged Sitting in Police Staff

Start date: September 9, 2019
Phase: N/A
Study type: Interventional

The primary aim of this study is to assess the feasibility of an intervention to reduce and break up prolonged sitting time in full-time police staff. The secondary aims of this study are to assess preliminary effects on patterns of sedentary behaviour (number of breaks, number of prolonged sitting bouts, average duration of prolonged sitting bouts, and total prolonged sitting duration), additional measures of sedentary behaviour (total sitting time, standing, and stepping), cardiometabolic risk markers, physiological stress (cortisol levels), physical health (self-report and postural stability), psychological wellbeing and mood, work stress (self-reported), and work performance (job satisfaction and productivity).